Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	June 8, 2023
Length of Meeting:	2 hours
Location of Meeting:	DMAS Board Room 102

Members Present:
John Morgan, MD, Chief Clinical Innovation Officer, Chair
Rachel Cain, PharmD
Elizabeth Gaughan, MD
Kristi Fowler, RPh
Melissa Chouinard, MD
Denise Lowe, PharmD
Seth Brant, MD
Matthew Estes, PharmD

Members Not Present:
Kathryn Reid, PhD
Wendy Nash, PharmD
Michele Thomas, PharmD
Denese Gomes, NP

DMAS Attendees:
Lisa Price Stevens, MD, MPH, MBA, FACP, CHIE, Chief Medical Officer
MaryAnn McNeil, RPh, Pharmacy Manager
JoeMichael Fusco, PharmD, MCO Pharmacy Compliance Manager
Rhonda Newsome, Senior Research Analyst

Contractors:
Nancy Eldin, PharmD, Pharmacist Account Executive, Magellan Rx Management
Jeni Hodzic, CPhT, Senior Account Management Specialist, Magellan Rx Management
Jenni Pandak, RPh, Senior Director, Clinical Account Management, Magellan Rx Management

Visitors:
Brad Burmeister
Brad Leiser
Doug Loock
Heidi Dix

Jane Oshinsky
Joe Kupiec
Kathy Bernstein
Keri Smith
Laurie Mauthe
Mark Santry
Nina Hodge
Wallene Bullard

Call to Order and Introductions

Dr. John Morgan welcomed and thanked everyone for attending the DUR meeting.

Dr. Morgan called the meeting to order at 1:07 pm.

Dr. Morgan introduced the new DMAS Chief Medical Officer:

- Lisa Price Stevens, MD, MPH, MBA, FACP, CHIE

Minutes – March 9, 2023

Dr. Melissa Chouinard motioned to approve the March 9, 2023 meeting minutes as submitted. Dr. Morgan seconded the motion.

By-Laws Review

Dr. Morgan gave an update on status of the DUR By-Laws. Voting on the DUR By-Laws is pending due to DMAS' performing an additional review.

New Drugs

The DUR Board reviewed Jaypirca™ (pirtobrutinib), Joenja® (leniolisib), Krazati™ (adagrasib), Orserdu™ (elacestrant) and Tezspire® Pen (tezepelumab-ekko). The Impact Reports and the report for the utilization of these 5 new DUR drugs for FFS and MCOs were reviewed.

The DUR Board reviewed the current service authorization (SA) class criteria for Oral Oncology – Other Cancer Drugs. The board discussed to update question number 1 to state "Is the prescriber an oncologist or in consultation with an oncologist?". The board is also interested in rewording question number 5 – "Does the member have a disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread?". DMAS will research both questions and bring back information to the board for further discussions. After discussion by the board, Dr. Morgan motioned to accept the SA criteria with the following new updates: add the new drug Jaypirca™ to

the SA criteria along with the FDA approved indications and minimum age; update question number 6 to “Has the member been assessed for toxicity?”; and include both brand name and generic name of each drug and identify the ones that have a generic available on the market on the SA form. Dr. Elizabeth Gaughan seconded the motion.

The DUR Board discussed the SA criteria for Joenja®. After much discussion by the board, Dr. Morgan motioned to accept the SA criteria with the following changes: question number 1 will be updated to state “Is the member 12 years of age or older and weighing ≥ 45 kg?”; question number 2 will be updated to state “Does the member have a confirmed diagnosis of APDS, as demonstrated by the presence of an activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)-associated genetic PI3Kδ mutation with a documented variant in either *PIK3CD* or *PIK3R1*?”; and question number 10 will be updated to state “Has the member been assessed for toxicity?”. Dr. Rachel Cain seconded the motion.

The DUR Board reviewed the current SA class criteria for Oral Oncology – Lung Cancer and Other Neoplasm Drugs. The board discussed revisingquestion number 1 to state “Is the prescriber an oncologist or in consultation with an oncologist?”. The board is also interested in rewording question number 5 – “Does the member have a disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread?”. DMAS will research both questions and bring back information to the board for further discussions. After discussion by the board, Dr. Morgan motioned to accept the SA criteria with the following new updates: add the new drug Krazati™ to the SA criteria along with the FDA approved indications and minimum age; updates to the Oral Oncology – Lung Cancer and Other Neoplasm Drugs SA form to be consistent with the other oncology SA forms with the drugs, minimum age, and FDA approved indications being in a table format; include both brand name and generic name of each drug and identify the ones that have a generic available on the market on the SA form; and update question number 6 to “Has the member been assessed for toxicity?”. Kristi Fowler seconded the motion.

The DUR Board discussed the SA criteria for Tezspire® Pen. Tezspire® Pen was added to the current Fasenra® Autoinjector Pen and Nucala® Prefilled Autoinjector and Syringe SA fax form. After much discussion by the board, Dr. Morgan motioned to accept the SA criteria with the following changes: question number 9 will be revised to state “Does the member continue to meet criteria numbers 1 – 6?”; questions number 10, 18, 26, and 37 will berevised to state “Has the member been assessed for toxicity?”; and remove the bullet under question number 11 that states “Two fold or greater decrease in inhaled corticosteroid use for at least 3 days”. Dr. Seth Brant seconded the motion.

The DUR Board reviewed the new SA class criteria for Oral Oncology – Breast Cancer and Other Neoplasm Drugs. The new criteria combines all the breast cancer oral oncology drugs to create one SA criteria for the entire class. This new SA form will eliminate the single SA criteria forms for individual breast cancer oral oncology drugs. The DUR Board also reviewed the utilization of these breast cancer oral oncology drugs for FFS. The board discussed revising question number 1 to state "Is the prescriber an oncologist or in consultation with an oncologist?". The board also discussed revising question number 5 – "Does the member have a disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread?". DMAS will research both questions and bring back information to the board for further discussions. Dr. Morgan motioned to accept the SA criteria with the following new updates: question number 6 will be updated to state "Has the member been assessed for toxicity?"; remove the older breast cancer drugs from the SA form and only keep the following breast cancer drugs on the SA form (Ibrance®, Kisqali®, Kisqali-Femara Co-Pack®, Nerlynx®, Orserdu™, Piqray®, Talzenna®, Tukysa®, and Verzenio®); include both brand name and generic name of each drug and identify the ones that have a generic available on the market on the SA form; and question number 3 will be revised to state "Has the prescriber counseled the member on adverse effects of therapy (i.e.. To include the potential risk of fetal toxicity)?". Dr. Cain seconded the motion.

MRx Pipeline and DUR Quarterly Newsletter- The April 2023 MRx Pipeline Report and the March 2023 DUR Quarterly Newsletter were both available on the DUR Webportal for review.

Topics for Discussion

Compounding of Hyftor™ – The DUR Board reviewed and discussed the Compound Claims with Sirolimus reports for FFS and MCOs.

Concurrent Use of Opioids and Benzodiazepines – The DUR Board reviewed Concurrent Use of Opioids and Benzodiazepines reports for FFS and MCOs.

Concurrent Use of Opioids and Antipsychotics – The DUR Board reviewed Concurrent Use of Opioids and Antipsychotics reports for FFS and MCOs.

Overlaps in Opioids, Benzodiazepines and Antipsychotics – The DUR Board reviewed Overlaps in Opioids, Benzodiazepines and Antipsychotics reports for FFS and MCOs.

Anticholinergic Load – The DUR Board reviewed Anticholinergic Load reports for FFS and MCOs.

Reports

ProDUR

The DUR Board reviewed and discussed the ProDUR reports.

RetroDUR

I. Recent RetroDUR Activity

The DUR Board reviewed the Recent RetroDUR Activity reports.

II. RetroDUR Criteria Estimates

The DUR Board reviewed the Criteria Exception Estimates Reports. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for Fee-For-Service (FFS) and each individual Managed Care Organization (MCO) plan.

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. These reports have been updated to exclude the medical claims and only include pharmacy claims.

Next DUR Meeting

September 14, 2023

Dr. Morgan motioned to adjourn the meeting. Dr. Chouinard seconded the motion. Meeting adjourned at 3:07 pm.